Trials / Completed
CompletedNCT05146973
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radioisotope for the treatment of PSMA-expressing tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 177Lu-DOTA-TLX591 | TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591) |
Timeline
- Start date
- 2022-08-30
- Primary completion
- 2023-07-30
- Completion
- 2024-03-24
- First posted
- 2021-12-07
- Last updated
- 2024-12-19
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05146973. Inclusion in this directory is not an endorsement.